Amicus widens UPenn gene therapy collaboration

Amicus Therapeutics announced it has expanded a gene therapy collaboration with the University of Pennsylvania to build out its presence in treating inherited metabolic disorders. Amicus' marketed product Galafold treats one such disorder, Fabry disease, by stabilizing a key enzyme, but a gene therapy project under the UPenn collaboration would compete with Galafold.